MHRA informeert naar welke medicijnen van veiligheidskenmerken voorzien zouden moeten worden

MHRA is consulting on products that should have the necessary ‘safety features’ in accordance with European law: the 'black' (non-prescription medicines that shall bear the safety features) and 'white' (prescription medicines that shall not bear the safety features) list.
Directive 2011/62/EU (‘Falsified Medicines Directive’) introduced obligatory ‘safety features’ to verify the authenticity of medicinal products. All prescription medicines will bear the safety features unless they are listed by the European Commission, all non-prescription medicines will not bear the safety features unless they are listed. MHRA seeks views on products that should be listed (MHRA website, 1 augustus 2014).
Klik hier voor meer informatie over de raadpleging.

Dit bericht is ook opgenomen in ons maandelijkse overzicht, de NVC Members-only Update. Heeft u vragen, neem dan contact met ons op via e-mail of bel: +31-(0)182-512411.